Aguilar J - Search Results

1

Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection.

Akbar SMF, Al Mahtab M, Yoshida O, Aguilar J, Gerardo GN, Hiasa Y. Akbar SMF, et al. Among authors: aguilar j. Biomedicines. 2023 Jul 8;11(7):1944. doi: 10.3390/biomedicines11071944. Biomedicines. 2023. PMID: 37509583 Free PMC article. Review.

2

Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B.

Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S. Al-Mahtab M, et al. Hepatol Int. 2013 Oct;7(4):981-9. doi: 10.1007/s12072-013-9486-4. Epub 2013 Nov 9. Hepatol Int. 2013. PMID: 26202028

3

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).

Al Mahtab M, Akbar SMF, Aguilar JC, Guillen G, Penton E, Tuero A, Yoshida O, Hiasa Y, Onji M. Al Mahtab M, et al. PLoS One. 2018 Aug 22;13(8):e0201236. doi: 10.1371/journal.pone.0201236. eCollection 2018. PLoS One. 2018. PMID: 30133478 Free PMC article. Clinical Trial.

4

Role of Pegylated Interferon in Patients with Chronic Liver Diseases in the Context of SARS-CoV-2 Infection.

Akbar SM, Mahtab MA, Aguilar JC, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Akbar SM, et al. Euroasian J Hepatogastroenterol. 2021 Jan-Jun;11(1):27-31. doi: 10.5005/jp-journals-10018-1341. Euroasian J Hepatogastroenterol. 2021. PMID: 34316461 Free PMC article.

The role of Peg-IFN for pre- or postexposure prophylaxis in the acquisition of SARS-CoV-2 infection and influencing the natural course of COVID-19 remains to be clarified. HOW TO CITE THIS ARTICLE: Akbar SMF, Mahtab MA, Aguilar JC, et al. Role of Pegylated Interferon in Pa …

The role of Peg-IFN for pre- or postexposure prophylaxis in the acquisition of SARS-CoV-2 infection and influencing the natural course of CO …

5

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial.

Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Akbar SMF, et al. Pathogens. 2021 Nov 5;10(11):1440. doi: 10.3390/pathogens10111440. Pathogens. 2021. PMID: 34832596 Free PMC article.

6

The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial.

Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Khan S, Penton E, Gerardo GN, Hiasa Y. Akbar SMF, et al. Vaccines (Basel). 2021 Dec 30;10(1):45. doi: 10.3390/vaccines10010045. Vaccines (Basel). 2021. PMID: 35062707 Free PMC article.

7

Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside.

Akbar SMF, Al Mahtab M, Khan S, Yoshida O, Aguilar JC, Gerardo GN, Hiasa Y. Akbar SMF, et al. Vaccines (Basel). 2022 May 10;10(5):746. doi: 10.3390/vaccines10050746. Vaccines (Basel). 2022. PMID: 35632502 Free PMC article. Review.

8

Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study.

Yoshida O, Akbar SMF, Imai Y, Sanada T, Tsukiyama-Kohara K, Miyazaki T, Kamishita T, Miyake T, Tokumoto Y, Hikita H, Tsuge M, Shimizu M, Al Mahtab M, Aguilar JC, Guillen G, Kohara M, Hiasa Y. Yoshida O, et al. Hepatol Res. 2023 Mar;53(3):196-207. doi: 10.1111/hepr.13851. Epub 2022 Nov 18. Hepatol Res. 2023. PMID: 36399406

9

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B.

Aguilar JC, Aguiar JA, Akbar SMF. Aguilar JC, et al. Vaccines (Basel). 2022 Dec 7;10(12):2087. doi: 10.3390/vaccines10122087. Vaccines (Basel). 2022. PMID: 36560498 Free PMC article. Review.

10

Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment.

Al Mahtab M, Akbar SMF, Aguilar JC, Yoshida O, Khan S, Gerardo GN, Hiasa Y. Al Mahtab M, et al. Front Med (Lausanne). 2023 Feb 8;10:1032531. doi: 10.3389/fmed.2023.1032531. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36844221 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,064 results

Search Page